Foghorn Therapeutics Inc. Share Price & Technical Analysis
FHTX · $4.22 (+1.44%)
Healthcare / Biotechnology
$4.22
+1.44%
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mut…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-11% return in May, -1% avg return in past 3 year May month.
-18% return in 2026, 46% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 6% | 0% | -13% | 0% | -11% | – | – | – | – | – | – | – | -18% |
| 25 | -12% | 20% | -24% | 14% | -2% | 15% | 11% | 0% | -2% | -10% | 9% | 15% | 31% |
| 24 | -50% | 141% | -14% | -18% | 5% | -3% | 23% | 26% | 13% | -17% | 3% | -42% | 66% |
| 23 | 32% | -37% | 9% | 5% | -6% | 11% | 30% | -16% | -35% | -33% | 27% | 52% | 39% |
| 22 | -33% | -38% | 58% | -23% | 9% | 5% | 7% | -31% | -15% | 0% | -24% | -4% | -87% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$254.52M
P/E ratio
—
52W high
$6.95
52W low
$3.27
Volume
1,61,746
Beta
2.97
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Foghorn Therapeutics Inc. share price today?
- Foghorn Therapeutics Inc. (FHTX) last traded around $4.22 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does FHTX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for FHTX. Download the app for real-time alerts.
- How can I analyze Foghorn Therapeutics Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.